Cryoport reports Q1 revenue of $52.3M, net loss $15.4M; FY2022 revenue guidance $260-265M

Cryoport, Inc.

2022-Q1 EPS reported -$0.31 revenue$52,302,000

Revenue $52.3M, down 2% YoY; net loss to common holders $15.4M ($0.31 loss per share) vs loss of $5.7M ($0.13) in Q1 2021.
Adjusted EBITDA $1.8M vs $7.2M in prior year; gross margin 42.7% vs 46.1%, impacted by $9.4M fire loss at New Prague plant.
Biopharma/Pharma revenue $43.0M (+1%); Animal Health $6.8M (-24%); Reproductive Medicine $2.5M (+32%). Commercial therapy revenue grew 53.5% to $3.9M.
Full-year 2022 revenue guidance $260-265M (17-19% growth). Cash and short-term investments $600M.
Record 609 clinical trials supported, 81 in Phase 3 (up from 69). Board authorized $100M share repurchase; 306,300 shares repurchased for $8.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.